Glenmark Pharmaceuticals receives FDA approval

Glenmark Pharmaceuticals Limited has secured final approval from the United States Food & Drug Administration (FDA) for its progesterone vaginal inserts. This regulatory milestone allows the company to market and distribute the product within the U.S. The approval is a significant step for Glenmark, potentially expanding its product portfolio and revenue streams in the competitive pharmaceutical market. It highlights the company's progress in developing and gaining regulatory clearance for its therapeutic offerings.